ELAN
NYSE · Pharmaceuticals
Elanco Animal Health Inc
$22.12
-2.08 (-8.60%)
Financial Highlights (FY 2026)
Revenue
4.74B
Net Income
-233,442,726
Gross Margin
55.0%
Profit Margin
-4.9%
Rev Growth
+2.3%
D/E Ratio
0.61
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 55.0% | 55.0% | 50.9% | 50.9% |
| Operating Margin | -4.3% | -3.9% | 24.9% | 24.8% |
| Profit Margin | -4.9% | -4.7% | 17.2% | 19.4% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 4.74B | 4.64B | 2.45B | 2.70B |
| Gross Profit | 2.61B | 2.55B | 1.25B | 1.37B |
| Operating Income | -206,362,770 | -181,639,601 | 611.44M | 668.94M |
| Net Income | -233,442,726 | -205,475,260 | 423.07M | 523.31M |
| Gross Margin | 55.0% | 55.0% | 50.9% | 50.9% |
| Operating Margin | -4.3% | -3.9% | 24.9% | 24.8% |
| Profit Margin | -4.9% | -4.7% | 17.2% | 19.4% |
| Rev Growth | +2.3% | +2.3% | +2.6% | +9.5% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 2.50B | 2.50B | 4.95B | 4.81B |
| Total Equity | 4.08B | 4.08B | 5.26B | 5.02B |
| D/E Ratio | 0.61 | 0.61 | 0.94 | 0.96 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 342.07M | 317.82M | 874.42M | 985.12M |
| Free Cash Flow | — | — | 633.64M | 593.63M |